Medical isotope company Shine Technologies has signed an agreement with Modawina Medical Company (MMC) to distribute Shine’s lutetium-177 (Lu-177) isotope in the United Arab Emirates (UAE).
Through the long-term agreement, MMC will distribute Shine's Ilumira non-carrier-added Lu-177 isotope to MMC's network of radiopharmaceutical manufacturers and nuclear medicine centers in the UAE.
In a statement, Shine noted that the strategic partnership with MMC for the distribution of Ilumira will expand the company's global reach as a supplier of isotopes for cancer treatment in the Europe, Middle East, and Africa (EMEA) region.
Ilumira is used in targeted cancer therapies to deliver radiation to cancer cells while minimizing damage to surrounding healthy tissue.
The U.S. Food and Drug Administration (FDA) expanded the approved indications for Lu-177-based radiopharmaceuticals in treating metastatic prostate cancer in March.
